nm32-2668
mAbexperimentalTri-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2024 (NCT06299163)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1
- Adenocarcinoma of Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Leiomyosarcoma · Phase 1
- Liposarcoma · Phase 1
- Melanoma · Phase 1
- Mesothelioma, Malignant · Phase 1
- Ovarian Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
CD3E activator
- Serum albuminBINDING AGENT
ALB binding agent
ROR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Tri-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06299163 | Phase 1 | May 1, 2024 | Numab Therapeutics AG |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Numab Therapeutics AG | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1